Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced it will release its third quarter 2024 financial and operational results on November 7, 2024, before markets open. The company's management team will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. Interested parties can join via webcast or by dialing (800) 715-9871 / +1 (646) 307-1963 with Conference ID: 6251719.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha annunciato che rilascerà i suoi risultati finanziari e operativi del terzo trimestre 2024 il 7 novembre 2024, prima dell'apertura dei mercati. Il team di gestione dell'azienda terrà una conference call e un webcast alle 8:30 am ET nello stesso giorno per discutere i risultati e fornire un aggiornamento sull'azienda. Le parti interessate possono partecipare tramite webcast o telefonando al numero (800) 715-9871 / +1 (646) 307-1963 con ID conferenza: 6251719.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha anunciado que publicará sus resultados financieros y operativos del tercer trimestre de 2024 el 7 de noviembre de 2024, antes de la apertura del mercado. El equipo directivo de la compañía llevará a cabo una conferencia telefónica y un webcast a las 8:30 am ET el mismo día para discutir los resultados y ofrecer una actualización del negocio. Las partes interesadas pueden unirse a través del webcast o llamando al (800) 715-9871 / +1 (646) 307-1963 con el ID de la conferencia: 6251719.
Aurinia Pharmaceuticals (NASDAQ: AUPH)는 2024년 11월 7일 시장이 열리기 전에 2024년 3분기 재무 및 운영 결과를 발표할 것이라고 발표했습니다. 회사의 경영팀은 같은 날 오전 8:30 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 전화 회의 및 웹 캐스트를 개최할 예정입니다. 관심 있는 분들은 웹캐스트에 참여하거나 (800) 715-9871 / +1 (646) 307-1963로 전화를 걸어 회의 ID: 6251719로 참여할 수 있습니다.
Aurinia Pharmaceuticals (NASDAQ: AUPH) a annoncé qu'elle publiera ses résultats financiers et opérationnels du troisième trimestre 2024 le 7 novembre 2024, avant l'ouverture des marchés. L'équipe de direction de l'entreprise tiendra une conférence téléphonique et un webcast à 8h30 HE le même jour pour discuter des résultats et fournir une mise à jour sur l'entreprise. Les parties intéressées peuvent participer via le webcast ou en appelant le (800) 715-9871 / +1 (646) 307-1963 avec l'ID de conférence : 6251719.
Aurinia Pharmaceuticals (NASDAQ: AUPH) hat angekündigt, dass die finanziellen und operativen Ergebnisse für das dritte Quartal 2024 am 7. November 2024 vor Markteröffnung veröffentlicht werden. Das Managementteam des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben. Interessierte Parteien können über den Webcast teilnehmen oder telefonisch unter (800) 715-9871 / +1 (646) 307-1963 mit der Konferenz-ID: 6251719 anrufen.
- None.
- None.
Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.
Webcast & Conference Call Details
The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030222492/en/
Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
When will Aurinia Pharmaceuticals (AUPH) release Q3 2024 earnings?
What time is Aurinia Pharmaceuticals (AUPH) Q3 2024 earnings call?
How can I join Aurinia Pharmaceuticals (AUPH) Q3 2024 earnings call?
